Clinical trial
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months…
NCT00493285 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00493285 |
|---|---|
| Title | Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age |
| Official title | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy… |
| Acronym | CP149 |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human |
| Intervention type | Biological |
| Interventions | MEDI-534 |
| Enrollment | 49 |
| Start date | Jul 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jun 28, 2007 |
| Last update posted | Jul 19, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: